Måns Agrup

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

Anders Widmark, Adalsteinn Gunnlaugsson, L. Beckman et al. · The Lancet · 2019 · 840 citations

Surgical Oncology, Radiation Therapy, Medicine +8

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial

Per Fransson, Per Nilsson, Adalsteinn Gunnlaugsson et al. · The Lancet Oncology · 2021 · 151 citations

Radiation Medicine, Radiation Therapy, Medicine +8

C-erbB-2 overexpression and survival in early onset breast cancer

Måns Agrup, O. Stål, Karen Ege Olsen et al. · Breast Cancer Research and Treatment · 2000 · 66 citations

Tumor Biology, Breast Oncology, C-erbb-2 Overexpression +7

A national approach for automated collection of standardized and population-based radiation therapy data in Sweden

Tufve Nyholm, Caroline Olsson, Måns Agrup et al. · Radiotherapy and Oncology · 2016 · 26 citations

Adaptive Radiotherapy, Data Modeling, Radiation Medicine +15

OC-0599: Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPO-RT-PC trial

Anders Widmark, Adalsteinn Gunnlaugsson, L. Beckman et al. · Radiotherapy and Oncology · 2018 · 21 citations · Full text